SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has sponsored a supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM) focusing on classic congenital adrenal hyperplasia (CAH), ...

capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal ...

Crinetics Pharmaceuticals announced positive topline results from a Phase 2 study of atumelnant, a novel oral ACTH receptor antagonist, for treating congenital adrenal hyperplasia (CAH).

Adrenal insufficiency diagnosis was more accurate and reliable with baseline cortisol alongside DHEAS measurements.

Jefferies has upgraded Crinetics Pharmaceuticals (NASDAQ:CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant in the treatment ...

such as late-onset congenital adrenal hyperplasia and Cushing's syndrome. The more recent 2003 Rotterdam consensus workshop was in response to an increasing awareness that the clinical expression ...

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH ...

The U.S. Food and Drug Administration (FDA) has granted approval to crinecerfont, an innovative oral drug designed to treat classic congenital adrenal hyperplasia (CAH) in patients aged four years ...

Jefferies analyst Dennis Ding upgraded Crinetics (CRNX) to Buy from Hold with an unchanged price target of $55. The firm cites the pullback in ...

Pharmaceuticals announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia, CAH, study of ...